Letter: Clonidine Hydrochloride Extended-Release Oral Suspension for Pediatric Attention-Deficit/Hyperactivity Disorder: A Meaningful Addition to Clinical Practice?

Abstract

Get full access to this article

View all access options for this article.

References

Charach

, Yeung

, Volpe

, et al. Exploring stimulant treatment in ADHD: Narratives of young adolescents and their parents. BMC Psychiatry 2014;14:110; doi: 10.1186/1471-244X-14-110

Jain

, Segal

, Kollins

, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2011;50(2):171–179; doi: 10.1016/j.jaac.2010.11.005

Jang

, Choi

, Han

, et al. Effectiveness of clonidine in child and adolescent sleep disorders. Psychiatry Investig 2022;19(9):738–747; doi: 10.30773/pi.2022.0117

Kollins

, Jain

, Brams

, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics 2011;127(6):e1406–e1413; doi: 10.1542/peds.2010-1260

Ming

, Mulvey

, Mohanty

, et al. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther 2011;2:105–112; doi: 10.2147/AHMT.S15672

Prisant

. Transdermal clonidine skin reactions. J Clin Hypertens (Greenwich) 2002;4(2):136–138; doi: 10.1111/j.1524-6175.2001.00954.x

Tris Pharma, Inc. 2024. Onyda XR (clonidine hydrochloride) extended-release oral suspension [package insert]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217645s001lbl.pdf [Last accessed: April 11, 2026].